帕博利珠单抗治疗晚期复发性卵巢癌患者的抗肿瘤活性与安全性:II期KEYNOTE-100研究结果
这项II期研究评估帕博利珠单抗单药治疗复发性卵巢癌,A组为既往1–3线且无铂间期或治疗间期3–12个月,B组为既往4–6线且无铂间期或治疗间期≥3个月。A组客观缓解率7.4%,B组9.9%;确认集中CPS<1为4.1%、CPS≥1为5.7%、CPS≥10为10.0%。单药活性有限,PD-L1表达较高与较高缓解相关。
要点
- A组客观缓解率7.4%,B组9.9%,单药帕博利珠单抗在复发性卵巢癌中活性有限。
- 确认集客观缓解率:CPS<1为4.1%,CPS≥1为5.7%,CPS≥10为10.0%。
- 两队列中位无进展生存期均为2.1个月,毒性与其他单药帕博利珠单抗试验一致。
核心结论
- 单药帕博利珠单抗在复发性卵巢癌患者中显示有限的抗肿瘤活性。
- 较高的PD-L1表达与较高的缓解率相关。
研究设计与样本
- II期研究(NCT02674061)评估帕博利珠单抗治疗复发性卵巢癌,设A、B两个患者队列。
- A组既往接受1–3线治疗且无铂间期或治疗间期在3至12个月之间,入组285例,前100例作为PD-L1生物标志物分析的训练集。
- B组既往接受4–6线治疗且无铂间期或治疗间期≥3个月,入组91例。
- 帕博利珠单抗200 mg每3周静脉给药,直至疾病进展、毒性或完成2年治疗。
- 主要终点为按队列及按PD-L1表达(联合阳性评分CPS)由盲法独立中心评审按RECIST 1.1评估的客观缓解率。
主要发现
- A组客观缓解率为7.4%,B组为9.9%。
- A组中位缓解持续时间为8.2个月,B组未达到。
- A组疾病控制率为37.2%,B组为37.4%。
- 确认集中客观缓解率:CPS<1为4.1%,CPS≥1为5.7%,CPS≥10为10.0%。
- 两队列中位无进展生存期均为2.1个月;A组中位总生存期未达到,B组为17.6个月。
关键数值与推荐
- 基于训练集分析,选择CPS 1和CPS 10在确认集中进行评估。
- 确认集客观缓解率:CPS<1为4.1%,CPS≥1为5.7%,CPS≥10为10.0%。
- A组客观缓解率7.4%,B组9.9%;A组中位缓解持续时间8.2个月,B组未达到。
- A组疾病控制率37.2%,B组37.4%;两队列中位无进展生存期均为2.1个月。
- A组中位总生存期未达到,B组为17.6个月。
临床怎么用
- 单药帕博利珠单抗在复发性卵巢癌中显示有限活性,较高PD-L1表达与较高缓解相关。
- 毒性与其他单药帕博利珠单抗试验一致。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Advanced recurrent ovarian cancer (ROC) is the leading cause of gynecologic cancer-related death in developed countries and new treatments are needed. Previous studies of immune checkpoint blockade showed low objective response rates (ORR) in ROC with no identified predictive biomarker. PATIENTS AND METHODS: This phase II study of pembrolizumab (NCT02674061) examined two patient cohorts with ROC: cohort A received one to three prior lines of treatment with a platinum-free interval (PFI) or treatment-free interval (TFI) between 3 and 12 months and cohort B received four to six prior lines with a PFI/TFI of ≥3 months. Pembrolizumab 200 mg was administered intravenously every 3 weeks until cancer progression, toxicity, or completion of 2 years. Primary end points were ORR by Response Evaluation Criteria in Solid Tumors version 1.1 per blinded independent central review by cohort and by PD-L1 expression measured as combined positive score (CPS). Secondary end points included duration of response (DOR), disease control rate (DCR), progression-free survival (PFS), overall survival (OS), and safety. RESULTS: Cohort A enrolled 285 patients; the first 100 served as the training set for PD-L1 biomarker analysis. Cohort B enrolled 91 patients. ORR was 7.4% for cohort A and 9.9% for cohort B. Median DOR was 8.2 months for cohort A and not reached for cohort B. DCR was 37.2% and 37.4%, respectively, in cohorts A and B. Based on the training set analysis, CPS 1 and 10 were selected for evaluation in the confirmation set. In the confirmation set, ORR was 4.1% for CPS <1, 5.7% CPS ≥1, and 10.0% for CPS ≥10. PFS was 2.1 months for both cohorts. Median OS was not reached for cohort A and was 17.6 months for cohort B. Toxicities were consistent with other single-agent pembrolizumab trials. CONCLUSIONS: Single-agent pembrolizumab showed modest activity in patients with ROC. Higher PD-L1 expression was correlated with higher response. CLINICAL TRIAL NUMBER: Clinicaltrials.gov, NCT02674061.
引用
- Matulonis UA, Shapira-Frommer R, Santin AD, et al. Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study. Ann Oncol. 2019. PMID: 31046082. doi:10.1093/annonc/mdz135
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。